A large-scale RNA interference screen uncovers a new transcriptional regulatory program involving the histone H3 demethylase KDM3A, which mediates detachment-induced apoptosis (anoikis) in breast epithelial cells.
Mutations in budding yeast modeled after cancer-associated isocitrate dehydrogenase mutations lead to stabilization of heterochromatin and enhanced gene silencing through inhibition of specific histone demethylases by the oncometabolite D-2-hydroxyglutarate.
Biochemical approaches reveal that an epigenetic histone deacetylase complex called CoREST is slow to deacetylate histone H3 lysine-14 in nucleosomes, and this inhibits demethylation of histone H3 lysine-4 by the CoREST complex.
The maternally provided histone demethylase LSD1/KDM1A has an instrumental role at the beginning of life, shaping the histone methylation landscape and the transcriptional repertoire of the early mouse embryo.
More than 30 published articles have suggested that a protein kinase called MELK is an attractive therapeutic target in human cancer, but three recent reports describe compelling evidence that it is not.